psalexa
logo

Cancer/Tumor Profiling Market

Cancer/Tumor Profiling Market by Technology (Next Generation Sequencing (NGS), Quantitative Polymerase Chain Reaction (QPCR), Immunohistochemistry (IHC), In-situ Hybridization (ISH), Microarray), by Technique (Genomics, Proteomics, Epigenetics, Metabolomics), by Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics), by Geography (U.S., Canada, Germany, U.K., France, Japan, China, Brazil, Mexico) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

Published: November 2017
Report Code: LS10823
Available Format:
Pages: 161
Category : Biotechnology

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Technology

1.3.2 Market Segmentation by Technique

1.3.3 Market Segmentation by Application

1.3.4 Market Segmentation by Geography

1.3.5 Analysis Period

1.3.6 Market Data Reporting Unit

1.3.6.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Technology

4.1.1.1 NGS

4.1.1.2 QPCR

4.1.1.3 IHC

4.1.1.4 ISH

4.1.1.4.1 FISH

4.1.1.4.2 CISH

4.1.1.5 Microarray

4.1.2 By Technique

4.1.2.1 Genomics

4.1.2.2 Proteomics

4.1.2.3 Epigenetics

4.1.2.4 Metabolomics

4.1.3 By Application

4.1.3.1 Personalized medicine

4.1.3.2 Diagnostics

4.1.3.3 Biomarker discovery

4.1.3.4 Prognostics

4.1.3.5 Others

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Increasing number of new cancer cases

4.2.1.2 Rising utility of biomarkers in tumor profiling

4.2.1.3 Rise in availability of funding for cancer research

4.2.1.4 Increasing demand for next generation sequencing for cancer profiling

4.2.1.5 Impact analysis of drivers on market forecast

4.2.2 Restraints

4.2.2.1 High capital investments and low benefit ratio for biomarkers

4.2.2.2 Dearth of skilled professionals and infrastructure

4.2.2.3 Impact analysis of restraints on market forecast

4.2.3 Opportunities

4.2.3.1 Increasing use of point-of-care diagnostic tests

4.2.3.2 Rising demand for personalized medicine

4.3 Porter’s Five Forces Analysis

4.3.1 Bargaining Power of Buyers

4.3.2 Bargaining Power of Suppliers

4.3.3 Intensity of Rivalry

4.3.4 Threat of New Entrants

4.3.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

5.1 By Technology

5.1.1 ISH Technology by Type

5.2 By Technique

5.3 By Application

5.4 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Technology

6.2 By Technique

6.3 By Application

6.4 By Country

Chapter 7. Europe Market Size and Forecast

7.1 By Technology

7.2 By Technique

7.3 By Application

7.4 By Country

Chapter 8. Asia-Pacific Market Size and Forecast

8.1 By Technology

8.2 By Technique

8.3 By Application

8.4 By Country

Chapter 9. LATAM Market Size and Forecast

9.1 By Technology

9.2 By Technique

9.3 By Application

9.4 By Country

Chapter 10. MEA Market Size and Forecast

10.1 By Technology

10.2 By Technique

10.3 By Application

Chapter 11. Global Market Size and Forecast by Technology

11.1 Global NGS Market, by Region

11.2 Global QPCR Market, by Region

11.3 Global IHC Devices Market, by Region

11.4 Global ISH Market, by Region

11.5 Global Microarray Market, by Region

Chapter 12. Global Market Size and Forecast by Technique

12.1 Global Genomics Market, by Region

12.2 Global Proteomics Market, by Region

12.3 Global Epigenetics Devices Market, by Region

12.4 Global Metabolomics Market, by Region

Chapter 13. Global Market Size and Forecast by Application

13.1 Global Personalized Medicine Market, by Region

13.2 Global Diagnostics Market, by Region

13.3 Global Biomarker Discovery Market, by Region

13.4 Global Prognostics Market, by Region

Chapter 14. Competitive Landscape

14.1 Product Benchmarking of Key Players

14.2 Global Strategic Developments of Key Players

14.2.1 Product Launches and Approvals

14.2.2 Agreements, Partnerships and Collaborations

14.2.3 Facility Expansion

14.2.4 Other Developments

Chapter 15. Company Profiles

15.1 Illumina, Inc.

15.1.1 Business Overview

15.1.2 Product and Service Offerings

15.1.3 Key Financial Summary

15.1.4 Strategic Growth Plans

15.2 NeoGenomics Inc.

15.2.1 Business Overview

15.2.2 Product and Service Offerings

15.2.3 Key Financial Summary

15.2.4 Strategic Growth Plans

15.3 Caris Life Sciences, Inc.

15.3.1 Business Overview

15.3.2 Product and Service Offerings

15.3.3 Strategic Growth Plans

15.4 QIAGEN N.V.

15.4.1 Business Overview

15.4.2 Product and Service Offerings

15.4.3 Key Financial Summary

15.4.4 Strategic Growth Plans

15.5 Helomics Corp.

15.5.1 Business Overview

15.5.2 Product and Service Offerings

15.5.3 Strategic Growth Plans

15.6 Oxford Gene Technology

15.6.1 Business Overview

15.6.2 Product and Service Offerings

15.6.3 Strategic Growth Plans

15.7 HTG Molecular Diagnostics, Inc.

15.7.1 Business Overview

15.7.2 Product and Service Offerings

15.7.3 Key Financial Summary

15.7.4 Strategic Growth Plans

15.8 RiboMed Biotechnologies, Inc.

15.8.1 Business Overview

15.8.2 Product and Service Offerings

15.8.3 Strategic Growth Plans

15.9 Genomic Health, Inc.

15.9.1 Business Overview

15.9.2 Product and Service Offerings

15.9.3 Key Financial Summary

15.9.4 Strategic Growth Plans

15.1 NanoString Technologies, Inc.

15.10.1 Business Overview

15.10.2 Product and Service Offerings

15.10.3 Key Financial Summary

15.10.4 Strategic Growth Plans

Chapter 16. Appendix

16.1 Abbreviations

16.2 Related Report

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 5 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 6 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2013 – 2016)

TABLE 7 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2017 – 2023)

TABLE 8 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 10 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2013 – 2016)

TABLE 13 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2017 – 2023)

TABLE 14 DIFFERENT TYPE OF CANCERS AND THE AMOUNT FUNDED

 TABLE 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 19 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 20 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 21 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)

TABLE 22 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)

TABLE 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 24 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 25 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 26 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 27 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 28 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 29 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)

TABLE 30 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)

TABLE 31 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 32 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 33 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 34 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 35 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 36 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 37 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)

TABLE 38 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)

TABLE 39 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 40 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 41 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 42 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 43 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 44 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 45 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)

TABLE 46 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)

TABLE 47 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)

TABLE 48 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)

TABLE 49 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)

TABLE 50 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)

TABLE 51 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)

TABLE 52 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)

TABLE 53 GLOBAL NGS MARKET, BY REGION, $M (2013 – 2016)

TABLE 54 GLOBAL NGS MARKET, BY REGION, $M (2017 – 2023)

TABLE 55 GLOBAL QPCR MARKET, BY REGION, $M (2013 – 2016)

TABLE 56 GLOBAL QPCR MARKET, BY REGION, $M (2017 – 2023)

TABLE 57 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 – 2016)

TABLE 58 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2017 – 2023)

TABLE 59 GLOBAL ISH MARKET, BY REGION, $M (2013 – 2016)

TABLE 60 GLOBAL ISH MARKET, BY REGION, $M (2017 – 2023)

TABLE 61 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 – 2016)

TABLE 62 GLOBAL MICROARRAY MARKET, BY REGION, $M (2017 – 2023)

TABLE 63 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 – 2016)

TABLE 64 GLOBAL GENOMICS MARKET, BY REGION, $M (2017 – 2023)

TABLE 65 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 – 2016)

TABLE 66 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2017 – 2023)

TABLE 67 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 – 2016)

TABLE 68 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2017 – 2023)

TABLE 69 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 – 2016)

TABLE 70 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2017 – 2023)

TABLE 71 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 – 2016)

TABLE 72 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2017 – 2023)

TABLE 73 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 – 2016)

TABLE 74 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2017 – 2023)

TABLE 75 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 – 2016)

TABLE 76 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2017 – 2023)

TABLE 77 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 – 2016)

TABLE 78 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2017 – 2023)

TABLE 79 ILLUMINA, INC. – AT A GLANCE

TABLE 80 ILLUMINA, INC. – KEY FINANCIAL SUMMARY

TABLE 81 NEOGENOMICS INC.– AT A GLANCE

TABLE 82 NEOGENOMICS INC. – KEY FINANCIAL SUMMARY

TABLE 83 CARIS LIFE SCIENCES, INC.– AT A GLANCE

TABLE 84 QIAGEN N.V. – AT A GLANCE

TABLE 85 QIAGEN N.V. – KEY FINANCIAL SUMMARY

TABLE 86 HELOMICS CORP. – AT A GLANCE

TABLE 87 OXFORD GENE TECHNOLOGY – AT A GLANCE

TABLE 88 HTG MOLECULAR DIAGNOSTICS, INC. -AT A GLANCE

TABLE 89 HTG MOLECULAR DIAGNOSTICS, INC. – KEY FINANCIAL SUMMARY

TABLE 90 RIBOMED BIOTECHNOLOGIES, INC. - AT A GLANCE

TABLE 91 GENOMIC HEALTH, INC. - AT A GLANCE

TABLE 92 GENOMIC HEALTH, INC. – KEY FINANCIAL SUMMARY

TABLE 93 NANOSTRING TECHNOLOGIES, INC. – AT A GLANCE

TABLE 94 NANOSTRING TECHNOLOGIES, INC., – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 GLOBAL CANCER/TUMOR PROFILING MARKET SUMMARY

FIG 8 PORTER’S FIVE FORCES ANALYSIS

FIG 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 10 GLOBAL ISH TECHOLOGY MARKET, BY TYPE, $M (2013 – 2023)

FIG 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 13 WORLDWIDE MAJOR MARKETS FOR CANCER/TUMOR PROFILING

FIG 14 NORTH AMERICA CANCER/TUMOR PROFILING MARKET SNAPSHOT

FIG 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)

FIG 19 EUROPE CANCER/TUMOR PROFILING MARKET SNAPSHOT

FIG 20 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 21 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 22 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)

FIG 24 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SNAPSHOT

FIG 25 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 26 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 27 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 28 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)

FIG 29 LATAM CANCER/TUMOR PROFILING MARKET SNAPSHOT

FIG 30 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 31 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 32 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 33 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)

FIG 34 MEA CANCER/TUMOR PROFILING MARKET SNAPSHOT

FIG 35 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)

FIG 36 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)

FIG 37 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)

FIG 38 GLOBAL NGS MARKET, BY REGION, $M (2013 – 2023)

FIG 39 GLOBAL QPCR MARKET, BY REGION, $M (2013 – 2023)

FIG 40 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 – 2023)

FIG 41 GLOBAL ISH MARKET, BY REGION, $M (2013 – 2023)

FIG 42 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 – 2023)

FIG 43 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 – 2023)

FIG 44 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 – 2023)

FIG 45 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 – 2023)

FIG 46 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 – 2023)

FIG 47 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 – 2023)

FIG 48 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 – 2023)

FIG 49 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 – 2023)

FIG 50 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 – 2023)

FIG 51 ILLUMINA, INC. – REVENUE SPLIT BY GEOGRAPHY (2016)

FIG 52 NEOGENOMICS INC. – REVENUE SPLIT BY SEGMENT (2016)

FIG 53 QIAGEN N.V. - REVENUE SPLIT BY GEOGRAPHY (2016)

FIG 54 HTG MOLECULAR DIAGNOSTICS, INC. – REVENUE SPLIT BY PRODUCT (2016)

FIG 55 HTG MOLECULAR DIAGNOSTICS, INC. – REVENUE SPLIT BY SERVICES (2016)

FIG 56 GENOMIC HEALTH, INC. – REVENUE SPLIT BY GEOGRAPHY (2016)

FIG 57 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY PRODUCT AND SERVICES (2016)

FIG 58 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY GEOGRAPHY (2016) 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry